Zevra Therapeutics (KMPH) Short Interest Ratio & Short Volume → Don’t Miss Out on the AI Gold Rush That’s Just Getting Started (From Banyan Hill Publishing) (Ad) Free KMPH Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Short InterestStock Analysis Zevra Therapeutics Short Interest DataCurrent Short Volume1,370,000 sharesPrevious Short Volume1,450,000 sharesChange Vs. Previous Month-5.52%Dollar Volume Sold Short$7.38 millionShort Interest Ratio / Days to Cover6.5Last Record DateFebruary 15, 2023Outstanding Shares34,505,000 sharesFloat Size31,300,000 sharesShort Percent of Float4.38%Today's Trading Volume64,100 sharesAverage Trading Volume189,500 sharesToday's Volume Vs. Average34% Short Selling Zevra Therapeutics ? Sign up to receive the latest short interest report for Zevra Therapeutics and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort InterestDays to CoverShort Percent of FloatKMPH Short Interest Over TimeKMPH Days to Cover Over TimeKMPH Percentage of Float Shorted Over Time Ad Crypto 101 MediaSHOCKING Crypto Leak…A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024. Claim your free seat by clicking here now. Zevra Therapeutics Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 2/15/20231,370,000 shares $7.38 million -5.5%4.4%6.5 $5.39 1/31/20231,450,000 shares $7.92 million +5.8%4.6%5.9 $5.46 1/15/20231,370,000 shares $7.56 million -16.0%4.4%5.8 $5.52 12/30/20221,630,000 shares $7.48 million +5.2%5.2%7.8 $4.59 12/15/20221,550,000 shares $6.98 million +0.7%5.0%7.6 $4.50 11/30/20221,540,000 shares $7.33 million +6.2%4.9%8 $4.76 Get the Latest News and Ratings for KMPH and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Zevra Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 11/15/20221,450,000 shares $6.45 million -6.5%4.6%7.7 $4.45 10/31/20221,550,000 shares $8.68 million -4.3%5.0%8.8 $5.60 10/15/20221,620,000 shares $9.06 million -9.0%5.2%7.9 $5.59 9/30/20221,780,000 shares $11.11 million +0.6%5.7%8 $6.24 9/15/20221,770,000 shares $12.12 million +2.9%5.7%6.2 $6.85 8/31/20221,720,000 shares $9.39 million +4.2%5.5%5.6 $5.46 8/15/20221,650,000 shares $9.80 million -7.3%5.3%5 $5.94 7/31/20221,780,000 shares $9.97 million -4.3%5.7%4.7 $5.60 7/15/20221,860,000 shares $9.43 million -10.1%6.1%4.2 $5.07 6/30/20222,070,000 shares $9.23 million -29.6%6.8%4.2 $4.46 6/15/20222,940,000 shares $12.41 million -7.6%9.8%5.3 $4.22 5/31/20223,180,000 shares $14.72 million +4.6%10.6%6.2 $4.63 5/15/20223,040,000 shares $12.46 million -27.5%10.1%5.7 $4.10 4/30/20224,190,000 shares $18.73 million +0.7%13.9%8 $4.47 4/15/20224,160,000 shares $17.76 million +9.8%13.8%8 $4.27 3/31/20223,790,000 shares $19.06 million +1.6%12.4%7.6 $5.03 3/15/20223,730,000 shares $19.10 million +3.9%12.2%7.8 $5.12 2/28/20223,590,000 shares $21.29 million +3.8%11.7%7.6 $5.93 2/15/20223,460,000 shares $21.35 million +5.8%11.3%7 $6.17 1/31/20223,270,000 shares $23.58 million -0.6%11.5%6.8 $7.21 1/15/20223,290,000 shares $26.95 million +7.9%10.6%7.2 $8.19 12/31/20213,050,000 shares $26.57 million +0.3%10.0%7.2 $8.71 12/15/20213,040,000 shares $23.89 million +8.2%9.9%7.2 $7.86 11/30/20212,810,000 shares $22.00 million -12.2%9.2%6.8 $7.83 11/15/20213,200,000 shares $29.34 million -6.7%10.4%7.8 $9.17 10/29/20213,430,000 shares $32.59 million -1.7%11.2%8 $9.50 10/15/20213,490,000 shares $34.10 million -11.2%11.4%8.1 $9.77 9/30/20213,930,000 shares $36.67 million +3.7%12.8%8.5 $9.33 9/15/20213,790,000 shares $33.43 million +10.2%12.4%6.4 $8.82 8/31/20213,440,000 shares $31.99 million -0.9%11.3%4.6 $9.30 8/13/20213,470,000 shares $31.58 million No Change11.4%4.4 $9.10 12/15/2020740,500 shares $682,666.95 +1,206.0%N/A0.7 $0.92 11/30/202056,700 shares $62,370.00 +3.7%N/A0 $1.10 11/15/202054,700 shares $32,814.53 -58.6%N/A0.1 $0.60This Apple-like Innovator is Revolutionizing Healthcare (Ad)AI has infiltrated so many sectors, it's sent the demand for AI-friendly GPU computer chips rocketing. Nvidia has gone up more than 3x in the past year. It is now valued well over $2 trillion, making it one of the largest companies in the world.Click here to learn more about the booming eHealth industry KMPH Short Interest - Frequently Asked Questions What is Zevra Therapeutics' current short interest? Short interest is the volume of Zevra Therapeutics shares that have been sold short but have not yet been closed out or covered. As of February 15th, investors have sold 1,370,000 shares of KMPH short. 4.38% of Zevra Therapeutics' shares are currently sold short. Learn More on Zevra Therapeutics' current short interest. What is a good short interest ratio for Zevra Therapeutics? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. KMPH shares currently have a short interest ratio of 6.0. Learn More on Zevra Therapeutics's short interest ratio. What is a good short interest percentage for Zevra Therapeutics? Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 4.38% of Zevra Therapeutics' floating shares are currently sold short. Is Zevra Therapeutics' short interest increasing or decreasing? Zevra Therapeutics saw a decrease in short interest in February. As of February 15th, there was short interest totaling 1,370,000 shares, a decrease of 5.5% from the previous total of 1,450,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. What is Zevra Therapeutics' float size? Zevra Therapeutics currently has issued a total of 34,505,000 shares. Some of Zevra Therapeutics' outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. Zevra Therapeutics currently has a public float of 31,300,000 shares. How does Zevra Therapeutics' short interest compare to its competitors? 4.38% of Zevra Therapeutics' shares are currently sold short. Here is how the short interest of companies in the sector of "medical" compare to Zevra Therapeutics: Skye Bioscience, Inc. (0.29%), Rigel Pharmaceuticals, Inc. (2.86%), Omeros Co. (23.90%), Lifecore Biomedical, Inc. (6.04%), NuCana plc (0.35%), Organigram Holdings Inc. (5.43%), Zevra Therapeutics, Inc. (5.63%), Atossa Therapeutics, Inc. (8.43%), Generation Bio Co. (2.35%), Design Therapeutics, Inc. (6.75%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: Enbridge Inc. ($4.09 billion), Occidental Petroleum Co. ($3.00 billion), T. Rowe Price Group, Inc. ($2.35 billion), Coinbase Global, Inc. ($2.30 billion), Paramount Global ($2.04 billion), Etsy, Inc. ($1.90 billion), Voya Financial, Inc. ($1.77 billion), CarMax, Inc. ($1.67 billion), Royal Caribbean Cruises Ltd. ($1.58 billion), and Monolithic Power Systems, Inc. ($1.47 billion). View all of the most shorted stocks. What does it mean to sell short Zevra Therapeutics stock? Short selling KMPH is an investing strategy that aims to generate trading profit from Zevra Therapeutics as its price is falling. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Zevra Therapeutics? A short squeeze for Zevra Therapeutics occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of KMPH, which in turn drives the price of the stock up even further. How often is Zevra Therapeutics' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including KMPH, twice per month. The most recent reporting period available is February, 15 2023. More Short Interest Resources from MarketBeat Related Companies: Skye Bioscience Short Interest Rigel Pharmaceuticals Short Interest Omeros Short Interest Lifecore Biomedical Short Interest NuCana Short Interest Organigram Short Interest Zevra Therapeutics Short Interest Atossa Therapeutics Short Interest Generation Bio Short Interest Design Therapeutics Short Interest Short Interest Tools: Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:KMPH) was last updated on 4/23/2024 by MarketBeat.com Staff From Our PartnersThe A.I. story nobody is telling you (Read ASAP)TradeSmithHealthcare Takes A Big Step Forward With The Help Of AIThe Bull ReportThis Apple-like Innovator is Revolutionizing HealthcareWall Street StarDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill Publishingtop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsExposed: 10 CENT Crypto to Explode April 20th?True Market Insiders[Shocking] Elon Musk’s Plan To End BanksCrypto 101 Media